Table V.5: The Number of States Reporting Challenges Regarding Communication or Interactions with the Food and Drug Administration (FDA) Related to Drug Compounding Issues
Number of states (%)
Yes: state has experienced challenges No: state has not experienced any challenges N/A: state has not had any communication or interactions with FDA related to drug compounding issues No response
15 (30) 25 (50) 8 (16) 2 (4)

Source: GAO survey of state pharmacy regulatory bodies, survey question 33. | GAO-17-363SP
Note: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey.